Medications and treatments Archive

Aducanumab is a newly approved drug for Alzheimer’s disease with the potential to reduce amyloid-beta plaque buildup in the brain. There are other medications being studied to see if they can reduce amyloid-beta, such as a monoclonal antibody that targets amyloid-beta before it forms plaques, and a monoclonal antibody that takes aim at plaque that has already formed. Other experimental approaches try to prevent tau tangles in brain cells, reduce brain inflammation, or reduce the amount of amyloid-beta that is produced.

Addiction can affect anyone, but social determinants of health — the factors that influence a person's circumstances in life — can have a negative impact on a person's efforts to overcome addiction.  Poverty, employment status, education level, and systemic racism can make it harder for people to reach and maintain recovery.

Worldwide, over one million men are diagnosed with prostate cancer every year, and half will be given androgen deprivation therapy at some point. Whether certain types of this therapy are safer for the heart than others is an important question that is being studied, but the results from the first such trial were inconclusive and disappointing.

A new medication for the treatment of obesity has been approved by the FDA, and it received significant media attention in the months leading up to its approval. A high-dose injectable hormone, it already existed in a different form as a treatment for type 2 diabetes, but in this form and dosage it has advantages over other available weight-loss medications, as well as its own potential risks.